Cameron Peters - Karyopharm Therapeutics Executive
| KPTI Stock | USD 0.81 0.02 2.41% |
Executive
Mr. Cameron Peters is Principal Financial Officer, Principal Accounting Officer of the Company. He has over 25 years of experience in finance and was employed by the Company as its Vice President, Finance and Assistant Treasurer since January 2018. Prior to joining the Company, from December 2013 to December 2017, Mr. Peters served as Chief Financial Officer at 24M Technologies, Inc., a developer of nextgeneration lithiumion batteries. From September 2010 to November 2013, he served as an independent consultant providing finance and analytic consulting services to biotechnology and global health companies. He served as Vice President, Finance at Luminus Devices, a developer and manufacturer of lightemitting diodes, from April 2006 to August 2010. From October 2005 to April 2006, he served as Vice President, Financial and Strategic Analysis at Health Dialog, a disease management company. From 2002 until joining Health Dialog, Mr. Peters served as Director, Financial Planning and Analysis at Millennium Pharmaceuticals, Inc., a biopharmaceutical company since 2019.
| Age | 64 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 85 Wells Avenue, Newton, MA, United States, 02459-3298 |
| Phone | 617 658 0600 |
| Web | https://www.karyopharm.com |
Karyopharm Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3427) % which means that it has lost $0.3427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 1.10, while Return On Tangible Assets are projected to decrease to (0.62). As of now, Karyopharm Therapeutics' Other Current Assets are increasing as compared to previous years. The Karyopharm Therapeutics' current Asset Turnover is estimated to increase to 0.64, while Total Assets are projected to decrease to under 238.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Jeff Boerneke | Gossamer Bio | N/A | |
| Colin Rowlings | Gossamer Bio | 60 | |
| Kasra Kasraian | Bluebird bio | N/A | |
| Tsveta Milanova | Agios Pharm | 47 | |
| Rocio Hoyos | Kronos Bio | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Timothy Lowinger | Mersana Therapeutics | 60 | |
| James Burns | Agios Pharm | 46 | |
| Roman Necina | Hookipa Pharma | 56 | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Jasmin Tower | Generation Bio Co | N/A | |
| Chuck Miller | Mersana Therapeutics | N/A | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Charles Lin | Kronos Bio | 39 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Wes Trotter | Kronos Bio | N/A | |
| Clive Patience | Agios Pharm | 60 | |
Management Performance
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.34 |
Karyopharm Therapeutics Leadership Team
Elected by the shareholders, the Karyopharm Therapeutics' board of directors comprises two types of representatives: Karyopharm Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karyopharm. The board's role is to monitor Karyopharm Therapeutics' management team and ensure that shareholders' interests are well served. Karyopharm Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karyopharm Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, Chief Officer | ||
| Richard MBA, CEO President | ||
| Sohanya MBA, Executive Officer | ||
| Reshma MD, Chief VP | ||
| Kristin Abate, Chief VP | ||
| Cameron Peters, Principal Financial Officer, Principal Accounting Officer | ||
| Sharon MBA, CoFounder Board | ||
| Mr MS, VP Affairs | ||
| Elhan CFA, Senior Relations | ||
| Mansoor MD, Member Consultant | ||
| Stuart Poulton, Executive Officer | ||
| RPh RPh, Global Operations | ||
| Michael JD, General VP | ||
| Sarah Connors, Vice Communications |
Karyopharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Karyopharm Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.68) % | ||||
| Current Valuation | 166.64 M | ||||
| Shares Outstanding | 125.31 M | ||||
| Shares Owned By Insiders | 6.15 % | ||||
| Shares Owned By Institutions | 50.00 % | ||||
| Number Of Shares Shorted | 18.93 M | ||||
| Price To Earning | (3.90) X |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.